• Users Online: 290
  • Print this page
  • Email this page
REVIEW ARTICLE
Year : 2022  |  Volume : 27  |  Issue : 2  |  Page : 109-113

N-nitrosodimethylamine (NDMA) and some prescribed medicines: A mini-review


1 Department of Internal Medicine, Alex Ekwueme Federal Teaching Hospital, Abakaliki, Ebonyi State, Nigeria
2 Department of Medicine, Nnamdi Azikiwe University Teaching Hospital, Nnewi, Anambra State, Nigeria
3 Department of Medicine, Enugu State University Teaching Hospital, Enugu, Nigeria
4 Department of Medicine, University of Nigeria Teaching Hospital, Enugu, Nigeria

Correspondence Address:
Chidiebere V Ugwueze
Department of Internal Medicine, Alex Ekwueme Federal Teaching Hospital, Abakaliki, Ebonyi State.
Nigeria
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/ijmh.IJMH_15_21

Rights and Permissions

Recently, there have been notices of drug recalls by different pharmaceutical companies. This is based on the finding of high level of N-nitrosodimethylamine (NDMA) in such medications. These medications are useful in the management of some diseases which affect a significant percentage of the population. It is therefore necessary to evaluate the chemical substance (NDMA), the sources, mechanisms, and the effects it can pose on the users of implicated medications. It is also important to consider the possible ways to avert the entry of NDMA into the medications. The substance, NDMA, has been found to be present as an impurity in high concentration in certain drugs, especially metformin slow release, valsartan and ranitidine. The approved healthy daily intake of NDMA by Food and Drug Administration (FDA) is about 96 ng. However, the concentrations of NDMA found in these drugs were exceptionally high which led to their recall. The high level of NDMA may arise from contamination, direct synthetic process, or from the degradation process of the medicine. Chromatography is the best detection modality of NDMA. The carcinogenic risk is the most feared effect of accumulated NDMA beyond the acceptable limit. On the basis of the frequent recalls of these medications, it is therefore imperative that pharmacists, pharmacologists, and physicians are acquainted with the sources of NDMA. This is in view of the serious risk it can pose to patients’ safety and quality of life. These concerns have given rise to this review article.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed628    
    Printed30    
    Emailed0    
    PDF Downloaded70    
    Comments [Add]    

Recommend this journal